Nick Cannon hits back at Eminem with new diss track The Invitation
Although the company will continue to pursue “higher-risk, high reward” drug candidates such as pegilodecakin, these will be a smaller part of the portfolio in the future, said Chief Scientific Officer Daniel Skovronsky. Selpercatinib is the first drug from Loxo’s pipeline that Lilly has brought to market. Prior to the acquisition, Loxo won approval of …
Nick Cannon hits back at Eminem with new diss track The Invitation Read More »
